EBS · XBRL financial data

Emergent BioSolutions financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (EBS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	1,577	1,793	1,118	1,049	1,044	743
Revenue from contracts with customers	1,555	—	—	1,049	1,044	743
Cost of goods and services sold	524	748	693	705	681	326
Gross profit	925	891	383	318	—	—
Research and development	235	234	188	111	71	53
Selling, general and administrative	303	348	340	368	308	186
Operating income (loss)	434	353	(170)	(726)	(109)	100
Interest expense	31	35	37	88	71	59
Other income (expense)	5	(4)	(12)	9	13	54
Income tax expense (benefit)	102	84	(7)	29	48	30
Net income (loss)	305	231	(212)	(761)	(191)	53
Earnings per share, basic USD per share	5.79	4.32	(4.22)	(14.85)	(3.60)	0.98
Earnings per share, diluted USD per share	5.67	4.27	(4.22)	(14.85)	(3.60)	0.93
Weighted average shares, basic millions of shares	53	54	50	51	53	54
Weighted average shares, diluted millions of shares	54	54	50	51	53	57

Fiscal years (EBS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	621	576	643	112	100	205
Accounts receivable	231	275	159	191	155	84
Inventory	307	351	351	329	312	343
Prepaid and other current assets	37	70	58	48	27	26
Total current assets	1,196	1,272	1,210	680	599	663
Property and equipment, net	644	800	818	383	271	205
Right-of-use asset	31	28	19	16	12	11
Goodwill	267	225	218	0	0	0
Total assets	2,883	2,959	3,166	1,823	1,390	1,319
Accounts payable	136	129	104	112	61	56
Accrued liabilities	47	52	35	19	18	12
Current portion of long-term debt	34	32	957	414	0	—
Total current liabilities	385	374	1,229	651	162	132
Long-term debt	841	809	449	447	664	572
Lease liability, non-current	28	24	15	14	10	9
Total liabilities	1,436	1,340	1,779	1,174	907	796
Retained earnings (accumulated deficit)	727	958	739	(22)	(212)	(160)
Total stockholders' equity	1,447	1,619	1,388	649	483	523
Total liabilities and equity	2,883	2,959	3,166	1,823	1,390	1,319
Common shares outstanding (cover page) millions of shares	≈53	51	50	52	54	52

≈ Rounded on cover: the filing states this count rounded, and it sits more than 1% off the weighted shares for the period.

Fiscal years (EBS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	305	231	(212)	(761)	(191)	53
Stock-based compensation	51	42	45	23	18	16
Depreciation and amortization	50	124	143	125	109	96
Net cash from operating activities	536	321	(34)	(206)	59	171
Purchases of property and equipment	141	225	116	52	23	14
Net cash from investing activities	(151)	(225)	(381)	212	125	69
Proceeds from issuing common stock	—	0	0	8	0	0
Share repurchases	0	106	82	0	0	25
Net cash from financing activities	70	(141)	481	(536)	(190)	(137)
Net change in cash	454	(45)	66	(531)	(6)	104

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Emergent BioSolutions	176	110	100*	51.4M	—	Q3 FY26 10-QSep 30, 2026
Northwest Biotherapeutics	0.6	0.8	(7.2)*	1.7B	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Amarin	157	40	9.2*	not reported	—	Q3 FY26 10-QSep 30, 2026
Rigel Pharmaceuticals	61	79	31*	18.7M	—	Q2 FY26 10-QJun 30, 2026
Usana Health Sciences	169	223	23*	18.5M	—	Q2 FY26 10-QJul 4, 2026
Altimmune	63	not reported	(24)*	194.5M	13.5 quarters	Q2 FY26 10-QJun 30, 2026
Prothena Corp Public	288	1	(25)*	51.3M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Aura Biosciences	68	not reported	(33)*	103.7M	2.1 quarters	Q2 FY26 10-QJun 30, 2026
Nektar Therapeutics	39	10	(76)*	34.1M	9.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.